| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 48.3 | 50.2 |
| Gross profit | 38.4 | 39.7 |
| Net income | -12.6 | -16.3 |
| EPS (diluted, $ a share) | $-0.19 | $-0.26 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -3.9% |
|---|---|
| Gross margin | 79.5% |
| Operating margin | -23.9% |
10-Q filed with the SEC, NASDAQ: TMCI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Treace Medical Concepts, Inc.: key numbers
- Share price
- $4.42Close, Nov 16
- Market cap
- $290M
- Shares outstanding
- 65.56MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Treace Medical Concepts, Inc.
All →Treace Medical Concepts Financial Results
Treace Medical Concepts reported Q3 2026 revenue of $48.3 million, a 4% decrease year-over-year primarily due to a shift toward lower-priced minimally invasive products. Despite the revenue dip, the company improved its net loss by 23% to $12.6 million and achieved positive Adjusted EBITDA of $0.3 million through targeted expense reduction initiatives.
- Term
- Q3 2026
“We are encouraged by our third quarter performance, reflecting accelerated double-digit case volume growth and continued market share gains – driven by increasing adoption of our comprehensive range of best-in-class bunion systems, as well as our expanding portfolio of new technologies including our SuperBite™ compression screws.”
John T. Treace, CEO and Chairman of Treace Medical
“We continue to make disciplined investments in key growth initiatives with an emphasis on our product pipeline, while staying focused on improving profitability and reducing cash usage. We believe this balanced approach positions us to build momentum and deliver stronger growth to finish the year.”
John T. Treace, CEO and Chairman of Treace Medical